EUVIMEDEUVIMED entdecken
Metaanalyse

Cerebral embolic protection in patients undergoing transcatheter aortic valve implantation: an updated meta-analysis of randomised controlled trials

Moaz Ahmad, Yik Ting Chan, Obaid Ur Rahman, Kevin Vinod Joseph, Nimra Zuberi, Iqra Safdar, Shereen Asghar, Danish Ahmed, Toqeer Ahmed, Umbreen Nadeem, Reem Abukhater, Ahmad Mesmar und 5 weitere

Archives of Medical Science – Atherosclerotic Diseases · 30.06.2026 · 11 (1) · 149-158

DOI: 10.5114/amsad/222277 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Archives of Medical Science – Atherosclerotic Diseases, online erschienen am 30.06.2026. Verfasst von Moaz Ahmad und 16 weiteren Autor:innen. Die Arbeit nennt 32 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Transcatheter aortic valve implantation (TAVI) has become a standard treatment for patients with severe aortic stenosis. However, periprocedural cerebral embolisation remains a major complication, contributing to the risk of stroke and silent cerebral infarctions. Cerebral embolic protection devices (CEPDs) have been developed to mitigate this risk, but their clinical efficacy remains uncertain.

Methods

A systematic search of the PubMed/Medline, Embase, and Cochrane library databases was conducted for randomised controlled trials (RCTs) comparing CEPD use versus no CEPD in patients undergoing TAVI, from inception to 1 May 2025. The primary outcome was all-cause stroke. Risk ratios (RRs) and mean differences (MDs) were pooled using a random-effects model.

Results

Eight RCTs comprising 11,611 patients (5956 with CEPD and 5655 without CEPD) were included. CEPD use was not associated with a significant reduction in all-cause stroke (RR = 0.92, 95% CI: 0.74–1.15), disabling stroke (RR = 0.80, 95% CI: 0.57–1.12), or non-disabling stroke (RR = 0.82, 95% CI: 0.58–1.16). No significant differences were observed in all-cause mortality (RR = 1.09, p = 0.70), NIHSS worsening (RR = 1.21, p = 0.41), new ischaemic lesions (RR = 0.99, p = 0.70), or lesion volume on DW-MRI (MD = –78.89 mm³, p = 0.10). Similarly, no significant differences were found in the incidence of acute kidney injury or vascular complications (p > 0.05).

Conclusions

The use of CEPDs during TAVI was not associated with a reduction in stroke, mortality, or other adverse clinical outcomes. Further research may be needed to identify subgroups who could benefit from CEPD use.

Zitieren

APA

Ahmad, M., Chan, Y. T., Rahman, O. U., Joseph, K. V., Zuberi, N., Safdar, I., Asghar, S., Ahmed, D., Ahmed, T., Nadeem, U., Abukhater, R., Mesmar, A., George, R., Khan, H., Hassnain, S. M. A., Haider, M. S., & Ahmed, R. (2026). Cerebral embolic protection in patients undergoing transcatheter aortic valve implantation: an updated meta-analysis of randomised controlled trials. Archives of Medical Science – Atherosclerotic Diseases, 11(1), 149-158. https://doi.org/10.5114/amsad/222277

Vancouver

Ahmad M, Chan YT, Rahman OU, Joseph KV, Zuberi N, Safdar I, et al. Cerebral embolic protection in patients undergoing transcatheter aortic valve implantation: an updated meta-analysis of randomised controlled trials. Archives of Medical Science – Atherosclerotic Diseases. 2026;11(1):149-158. doi:10.5114/amsad/222277

BibTeX
@article{Ahmad2026,
  author = {Ahmad, Moaz and Chan, Yik Ting and Rahman, Obaid Ur and Joseph, Kevin Vinod and Zuberi, Nimra and Safdar, Iqra and Asghar, Shereen and Ahmed, Danish and Ahmed, Toqeer and Nadeem, Umbreen and Abukhater, Reem and Mesmar, Ahmad and George, Rowena and Khan, Haris and Hassnain, Syed Muhammad Ali and Haider, Muhammad Sajjad and Ahmed, Raheel},
  title = {Cerebral embolic protection in patients undergoing transcatheter aortic valve implantation: an updated meta-analysis of randomised controlled trials},
  journal = {Archives of Medical Science – Atherosclerotic Diseases},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {149--158},
  doi = {10.5114/amsad/222277}
}
Kostenlos starten →